Role of ROCK inhibitor in corneal reconstruction: promoting the proliferation, migration and adhesion of keratocytes

doi:10.3969/j.issn.2095-4344.2015.33.025

Abstract

Abstract:

BACKGROUND: With the deepen understanding on the biological function of Rho/ROCK pathway, new ROCK inhibitors continue to be discovered, and ROCK inhibitors show good promoting effects on the survival, proliferation and migration of keratocytes. Research on ROCK inhibitors will provide more donor materials or seed cells for regenerative medicine and clinical cell transplantation.

OBJECTIVE: To summarize and explore the progress in the treatment and application of corneal disease using the ROCK inhibitors Y-27632 and Y-39983.

METHODS: The PubMed database and CNKI database were retrieved by computer to search the relevant literature published between 2008 to 2015 using the key words of “corneal endothelial cell, corneal epithelial cell,
ROCK inhibitor, Y-39983, Y-27632” in English and Chinese, respectively. Relevant articles in line with the theme were screened and analyzed.

RESULTS AND CONCLUSION: Totally 264 papers were initially searched. At last, 45 papers were selected. Currently there are two main ROCK inhibitors: Y-27632 and Y-39983, but both of which are still in basic research stage and clinical testing stage. Y-27632 promotes the proliferation and activity of corneal epithelial stem cell after resuscitation; Y-39983 as a novel ROCK inhibitor can be better to inhibit Rho kinases activity than Y-27632, thereby more effectively promoting the healing of the corneal endothelium. There are many studies on the application of ROCK inhibitors in corneal treatment, but not a stable method established to obtain seed cells. Each method has its own advantages and disadvantages, and how to overcome these disadvantages and to find fast and stable access to seed cells is the future direction of development.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Cornea, Endothelial Cells, Eye

CLC Number:

R318

Zhang Shi-qi, Zhu Yun-fei, Guo Yong-long, Zheng Jia-fu, Chen Jian-su. Role of ROCK inhibitor in corneal reconstruction: promoting the proliferation, migration and adhesion of keratocytes[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(33): 5383-5388.

Figures/Tables 1

References

[1] Mueller BK,Mack H,Teusch N.Rhokinase,a promising drug target for neuro logical disorders.Nat Rev Drug Discov.2005; 4:387-398.
[2] 段为钢,袁胜涛,廖红,等. Rho激酶及其抑制剂的研究进展[J].药学学报，2007, 42(10):1013-1022.
[3] Moffatt SL,Cartwright VA,Stumpf TH.Centennial review of corneal transplantation.Clin Experiment Ophthalmol.2005; 33:642-657.
[4] Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003;110:1396-1402.
[5] Panda A,Vanathi M,Kumar A,et al.Corneal graft rejection.Surv Ophthalmol.2007;52: 375-396.
[6] Golchet G, Carr J, Harris MG. Why don’t we have enough cornea donors? A literature review and survey. Optometry. 2000;71:318-328.
[7] Olson MF. Applications for ROCK kinase inhibitio .Curr Opin Cell Biol.2008; 20(2):242-248.
[8] Hahmann C, Schroeter T.Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.Cell Mol Life Sci.2010; 67(2):171-177.
[9] Tanaka T, Nishimura D, Wu RC, et al. Nuclear Rho kinase, ROCK2, targets p300 acetltransferase. Biol chem. 2006; 281(22);15320-15329.
[10] Kiento K, Kidley AJ. Rocks: multifunctional kinase in cell beliaviour.Nat Rev Mol Cell Biol.2003;4(6):446-456.
[11] Rao PV, Deng PF, Kumar J, et al. Modulation of aqueous liumor outflow facility by the Rho kinase-specific inhibitor Y-27632.Invest Ophthalmol Vis Sci.2001;42 (5):1029-1037.
[12] 李斌. ROCK抑制剂Y-27632对角膜上皮的保护性作用及其机制的初步研究[D].济南大学,2013.
[13] Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing.Invest Ophthalmol Vis Sci.2014;55(1):318-329.
[14] 蒙青青,刘苏. ROCK抑制剂在眼科基础及临床应用研究进展[J]. 眼科新进展,2013;09:894-897.
[15] Nakajima E, Nakajima T, Minagawa Y, et al.Contribution of ROCK in contraction of trabecular meshwork:proposed mechanism for regulating aqueous outflow in monkey and human eyes. Pharm Sci.2005;94:701-708.
[16] Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys.Invest Ophthalmol Vis Sci.2007;48:3216-3222.
[17] Ishizaki T, Uehata M, Tamechika I,et al.Pharmacological properties of Y-27632, a specific inhibitor ofRho-associated kinases.Mol Pharmacol.2000;57 (5):976-983.
[18] Sangwan VS. Limbal stem cells in health and disease.Biosci Rep. 2001;21(4):385-405.
[19] Davanger M, Evensen A. Role of the pericorneal papillary structure in renewal of corneal epithelial. Nature.1971;229: 560-561.
[20] Nagasaki T,Zhao J.Centripetal movement of corneal epithelial cells in the normal adult mouse.Invest Ophthalmol Vis Sci. 2003;44(2):558-566.
[21] Collinson JM,Morris L,Reid AI, et al. Clonal analysis of patterns of growth, stem cell activity, and cell movement during the development and maintenance of the murine corneal epithelium.Dev Dyn.2002;224(4):432-440.
[22] Thoft RA,Rriend J.The X,Y,Z hypothesis of corneal epithelial maintenance. Invest Ophthalmol Vis Sci.1983;24:1442-1443.
[23] Yin J, Yu FS.Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol.2008;295: C378-C387.
[24] 马玲.ROCK抑制剂在角膜缘干细胞体外扩增和保存中的作用研究[D].青岛大学,2012.
[25] Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing.Invest Ophthalmol Vis Sci.2013;54(4):2493-2502.
[26] Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase(ROCK) inhibitor eye drops.Br J Ophthalmol. 2011; 95:1006-1009.
[27] Shanyi L, Chan W, Ying D, et al. The stimulatory effect of ROCK inhibitor on bovine cornealendothelial cells.Tissue Cell.2013;45(6):387-396.
[28] Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial cell sheet transplantation in a primate model.Invest Ophthalmol.Vis Sci.2007;48:4519-4526.
[29] Koizumi N,Sakamoto Y,Okumura N,et al.Cultivated corneal endothelial transplantation in a primate: possible future clinical application in corneal endothelial regenerative medicine. Cornea.2008;27:Suppl 1:S48-S55.
[30] Okumura N,Koizumi N,Ueno M,et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue.Am J Pathol.2012; 181(1): 268-277.
[31] Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol,2006;7:211-224.
[32] Abbott A. Cell culture: biology's new dimension. Nature.2003; 424: 870-872.
[33] Yamada K, Kamihira M, Iijima S. Enhanced cell aggregation and liver functions using polymers modified with a cell-specific ligand in primary hepatocyte cultures. Biosci Bioeng. 1999;88:557-562.
[34] Han Y, Liu XM, Liu H, et al. Cultivation of recombinant Chinese hamster ovary cells grown as suspended aggregates in stirred vessels. Biosci Bioeng.2006; 102: 430-435.
[35] Bi YL, Zhou Q, Du F, et al. Regulation of functional corneal endothelial cells isolated from sphere colonies by Rho-associated protein kinase inhibitor. Exp Ther Med.2013; 5(2):433-437.
[36] Tokushige H, Inatani M, Nemoto S, et al.Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci.2007;48:3216-3222.
[37] Mimura T,Yamagami S,Yokoo S, et al. Sphere Therapy for Corneal Endothelium Deficiency in a Rabbit Model. Investigative Ophthalmology & Visual Science. 2005;9(46): 3128-3135.
[38] Honjo M, Tanihara H, Inatani M, et al.Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci.2001;42:137-144.
[39] Waki M, Yoshida Y, Oka T, et al. Reduction of intraocular pressure by topical administration of an inhibitor of the Rhoassociated protein kinase.Curr Eye Res.2001;22: 470-474.
[40] 邱敬华. H-1152降眼压治疗青光眼的实验研究[D].南华大学, 2007.
[41] Wang RF1, Williamson JE, Kopczynski C, et al.Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma.2015;24(1):51-4.
[42] Lee JG, Kay EP.PI3-kinase/Rac1 and ERK1/2 regulate FGF-2-mediated cell proliferation through phosphorylation of p27 at Ser10 by KIS and at Thr187 by Cdc25A/Cdk2. Invest Ophthalmol Vis Sci.2011;52:417-426.
[43] Lee HT, Kay EP. Regulatory role of PI 3-kinase on expression of Cdk4 and p27, nuclear localization of Cdk4, and phosphorylation of p27 in corneal endothelial cells. Invest Ophthalmol Vis Sci.2003;44:1521-1528.
[44] Yamamoto M, Marui N, Sakai T, et al. ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. Oncogene.1993;8:1449-1455.
[45] Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science.1995;269:1270-1272.